FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair® (omalizumab) for the prevention of severe allergic reactions [..]